Skip to main content

A Phase 1/2 open label study of Nivolumab monotherapy or Nivolumab combined with Ipilimumab in subjects with advanced or metastatic solid tumors.

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Bristol-Myers Squibb Company

Start Date

April 1, 2014

End Date

March 31, 2024
 

Administered By

Duke Cancer Institute

Awarded By

Bristol-Myers Squibb Company

Start Date

April 1, 2014

End Date

March 31, 2024